Which of the following are approved agents for Opioid Treatment Programs (OTPs)?

Buprenorphine and Naltrexone are approved agents for Opioid Treatment Programs (OTPs) because they are specifically formulated to assist in the treatment of opioid use disorder. Buprenorphine is a partial agonist that helps reduce cravings and withdrawal symptoms without producing the full euphoric effects of stronger opioids. Naltrexone, on the other hand, is an opioid antagonist that blocks the effects of opioids, helping to prevent relapse in patients who have already detoxed.

These medications are integral parts of medication-assisted treatment (MAT), which is a comprehensive approach to help individuals recover from opioid addiction. They are utilized within OTPs under various regulatory frameworks to ensure safe and effective treatment.

In contrast, the other options do not align with the approved treatments for opioid use disorder. Heroin and Fentanyl are illicit substances and are not approved for OTPs as they contribute to addiction, rather than treating it. Acetaminophen and Ibuprofen are over-the-counter non-opioid analgesics and do not have a role in the treatment of opioid dependency. Codeine and Morphine, while they are opioids, are not utilized in OTPs for treatment as they can lead to continued substance use rather than recovery.